Tivdak
Pronunciation: TIFF-dack
Generic name: tisotumab
Dosage form: injection for intravenous use
Drug class: Miscellaneous antineoplastics
What is Tivdak?
Tivdak (tisotumab vedotin-tftv) is an injectable antibody-drug conjugate that may be used to treat women with cervical cancer that has returned or has spread to other parts of the body, and who have received chemotherapy that did not work or is no longer working.
- Tivdak is usually given as an intravenous (into a vein) infusion over 30 minutes, once every 3 weeks.
Tivdak is a first-in-its-class antibody-drug conjugate (ADC). The antibody part is a human IgG1 that targets tissue factor (TF) on the cell surface. TF is a protein expressed in cervical cancer cells that can promote tumor growth, angiogenesis, and metastases and also initiates blood clotting (extrinsic cascade). The small molecule drug, MMAE, is attached to the antibody by a link and is easily broken by protease enzymes. The ADC binds to TF-expressing cancer cells which then take up Tivdak and release the active MMAE which disrupts the microtubule network of actively dividing cells, stopping replication and leading to cell death. Because TF is also present in some normal cells, Tivdak can still harm normal cells.
Tivdak gained full FDA approval on April 29, 2024, after a clinically meaningful improvement in overall survival was reported by a phase III clinical trial. Before that, it was approved on September 20, 2021 under the accelerated approval designation and was contingent upon continued favorable results in clinical trials.
Tivdak success rate
A significant difference in overall survival was reported with Tivdak compared to single-agent chemotherapy (investigators' choice) in a phase III clinical trial of 502 women with advanced cervical cancer (253 received Tivdak and 249 received chemotherapy) (Martin et al, 2024).
- Those treated with Tivdak lived longer on average than those who received chemotherapy.
- The median overall survival (this means half the participants were still alive after this timeframe) was 11.5 months for Tivdak compared to 9.5 months for chemotherapy.
- The 12-month overall survival rate was 48.7% for Tivdak vs 35.3% for chemotherapy.
- The median progression-free survival (the period before the cancer gets worse) was 4.2 months for Tivdak vs 2.9 months for chemotherapy, a 33% reduction in risk (HR = 0.67; P < .0001).
- 30.4% of those receiving Tivdak vs 18.9% of those receiving chemotherapy were progression-free at 6 months. The median duration of response was about 5 months in each arm.
- Treatment-related side effects that occurred in those assigned Tivdak were generally of low grade and manageable, with fewer people experiencing grade ≥ 3 toxicities with Tivdak than with chemotherapy (29.2% vs 45.2%).
- The most common grade ≥ 3 toxicities with Tivdak were peripheral neuropathy (5.2%), ocular toxicities (3.2%), and bleeding (0.8%).
Related/similar drugs
Keytruda, fluorouracil, Avastin, cisplatin, pembrolizumab, carboplatin
Tivdak side effects
The most common side effects of Tivdak affecting 25% or more people who take it include:
- decreased red blood cell counts
- nausea
- nosebleeds
- numbness or tingling in your hands or feet
- tiredness
- hair loss (alopecia)
- eye problems
- changes in liver function blood tests
- bleeding (hemorrhage).
Serious side effects and warnings
Tivdak can cause serious side effects and carries a Boxed Warning for eye toxicity. Other serious side effects include peripheral neuropathy (nerve damage in the hands and feet), serious skin reactions, and bleeding.
Eye problems. These are common and can be severe. Tivdak can cause changes to the surface of your eye that can lead to dry eyes, eye redness, eye irritation, corneal ulcers, blurred vision, and severe vision loss. Tell your healthcare provider if you develop new or worsening vision changes or eye problems during treatment.
- Your healthcare provider will send you to an eye specialist to check your eyes before you start treatment with Tivdak, before each infusion for your first 9 infusions of Tivdak, and as needed for any new or worsening signs or symptoms of eye problems.
- Your healthcare provider will ask if you have any signs or symptoms of eye problems before each infusion. You will be referred to an eye specialist for any new or worsening signs or symptoms of eye problems.
Your healthcare provider will prescribe 3 different types of eye drops before you start treatment with Tivdak. Bring the eye drops with you to each infusion and use them as directed by your healthcare provider to reduce your risk of eye problems:
- Use 1 drop of steroid eye drops in each eye before each infusion and continue to use your eye drops 3 times a day for 3 days after each infusion.
- Use vasoconstrictor eye drops right before each infusion.
- Use lubricating eye drops throughout treatment and for 30 days after your last dose of Tivdak.
- Do not wear contact lenses throughout your treatment with Tivdak unless you are told to use them by your eye specialist.
Peripheral neuropathy (nerve problems in the hands or feet). These are common with Tivdak, and can also be serious. Tell your healthcare provider right away if you get numbness or tingling in your hands or feet or muscle weakness.
Bleeding (hemorrhage) is common with Tivdak and can also be serious. Tell your healthcare provider or get medical help right away if you get signs or symptoms of bleeding during treatment such as:
- blood in your stools or black stools (looks like tar)
- unusual vaginal bleeding
- blood in your urine
- any unusual or heavy bleeding
- cough up or vomit blood.
Severe or life-threatening inflammation of the lungs that can lead to death. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Severe skin reactions. Tivdak may cause severe or life-threatening skin reactions that can lead to death. Tell your healthcare provider or get medical help right away if you get signs or symptoms of a severe skin reaction during treatment, including:
- skin reactions that look like rings (target lesions)
- fever or flu-like symptoms
- rash or itching that continues to get worse
- swollen lymph nodes
- blistering or peeling of the skin
- painful sores or ulcers in your mouth, nose, throat, or genital area
It is not known if Tivdak is safe and effective in children.
These are not all of the possible side effects of Tivdak. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Before taking
Before receiving Tivdak, tell your healthcare provider about all of your medical conditions, including if you:
- have a history of vision or eye problems
- have numbness or tingling in your hands or feet
- have bleeding problems
- have liver problems
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed.
Pregnancy
Tivdak can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Tivdak.
If you are a female who can become pregnant your healthcare provider should do a pregnancy test before you start treatment with Tivdak and you should use an effective birth control during treatment and for 2 months after your last dose.
Males with female partners who can become pregnant should use effective birth control during treatment and for 4 months after their last dose of Tivdak.
Fertility
Tivdak may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
Breastfeeding
It is not known if Tivdak passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after your last dose.
How is Tivdak administered?
Tivdak is administered by a healthcare professional through an intravenous (IV) infusion into your vein over 30 minutes.
Tivdak is usually given every 3 weeks.
Your healthcare provider will:
- decide how many infusions you need
- put cold packs on your eyes during each infusion
- may decrease your dose, temporarily stop, or completely stop treatment if you have side effects.
What other drugs will affect Tivdak?
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Tivdak with certain other medicines may cause side effects.
MMAE is a substrate of CYP3A4 liver enzymes. Using Tivdak with strong CYP3A4 inhibitors, such as clarithromycin, erythromycin, and isoniazid, may increase blood levels of MMAE increasing the risk of Tivdak side effects.
This is not a complete list of interactions. Tell your healthcare provider about all the medicines you take.
Storage
Tivdak is a hazardous substance. Healthcare providers should follow special handling and disposal procedures.
Store Tivdak vials refrigerated at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light. Do not freeze. Do not shake.
If not used immediately, reconstituted vials may be stored for up to 24 hours in refrigeration at 2°C to 8°C (36 °F to 46 °F) or at room temperature up to 25°C (77°F) for up to a maximum of 8 hours before dilution.
Do not freeze. Do not be exposed to direct sunlight. Discard unused vials with a reconstituted solution beyond the recommended storage time.
Ingredients
Active ingredient: tisotumab vedotin-tftv
Inactive ingredients: d-mannitol, l-histidine, l-histidine monohydrochloride, and sucrose.
Who makes Tivdak?
Seagen Inc makes Tivdak.
References
- Tivdak Package Insert
- MartÃn A, Slomovitz B, Fujiwara K, et al. InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer. International Journal of Gynecologic Cancer. 34. A4-A5. 10.1136/ijgc-2024-ESGO.7.
More about Tivdak (tisotumab vedotin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.